Evidence map›Paper›PMID 42169932›Full record

ArticleJournal of gastrointestinal oncology2026

An exploratory nomogram model with

Shichang Li, Ai'nan Guo, Xue Wang, Ying Tian, Fang Zhang, Lingge Wei, Peng Fu

Abstract read
In one paragraph

Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shichang LiDepartment of Nuclear Medicine, Peking University People's Hospital, Beijing, China.
Ai'nan GuoDepartment of Ultrasound Medicine, North Branch, the Second Hospital of Hebei Medical University, Shijiazhuang, China.
Xue WangDepartment of Nuclear Medicine, the Third Hospital of Hebei Medical University, Shijiazhuang, China.
Ying TianDepartment of Nuclear Medicine, the Third Hospital of Hebei Medical University, Shijiazhuang, China.
Fang ZhangDepartment of Nuclear Medicine, the Third Hospital of Hebei Medical University, Shijiazhuang, China.
Lingge WeiDepartment of Nuclear Medicine, the Third Hospital of Hebei Medical University, Shijiazhuang, China.
Peng FuDepartment of Nuclear Medicine, the Third Hospital of Hebei Medical University, Shijiazhuang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There are still difficulties in dividing patients into an microvascular invasion (MVI) high-risk and non-high-risk group among hepatocellular carcinoma (HCC) patients based on the pathology findings. This study investigated preoperative fluorine-18-fluorodeoxyglucose ( Methods: A retrospective analysis was conducted involving 79 HCC patients undergoing liver transplantation with preoperative Results: LASSO regression identified TMRmax and tumor diameter as significant factors that are associated with high-risk MVI. Multivariate analysis confirmed the independence of these two predictors: TMRmax [odds ratio (OR) =1.757, 95% confidence interval (CI): 1.124-2.746; P=0.01] and tumor diameter (OR =1.247, 95% CI: 1.067-1.456; P=0.005). ROC curve analysis indicated that a TMRmax ≥2.1 achieved a sensitivity of 70.27% and a specificity of 64.29% [area under the ROC curve (AUC) =0.716], while a tumor diameter ≥8.3 cm had a sensitivity of 51.35% and a specificity of 90.48% (AUC =0.729). The combined model demonstrated improved predictive performance (C-index =0.779, 95% CI: 0.672-0.865) with the nomogram demonstrating good calibration. Conclusions: TMRmax and tumor diameter may be closely associated with high-risk MVI in HCC. The exploratory model combining TMRmax and tumor diameter may help on preoperative risk stratification. Due to the small sample size from a single center, the results of this study warrant validation.

Indexed as

fluorine-18-fluorodeoxyglucose (18F-FDG)Hepatocellular carcinoma (HCC)liver transplantationmicrovascular invasion (MVI)positron emission tomography/computed tomography (PET/CT)

Identifiers

PMID42169932
PMCPMC13188018

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.